Targeting the HGF/Met signaling pathway in cancer therapy.

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res (2014) 1.08

Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol (2013) 1.07

Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol (2014) 1.01

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol (2013) 0.99

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer (2014) 0.97

Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One (2014) 0.94

HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget (2014) 0.92

HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics. Int J Mol Sci (2013) 0.92

Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One (2013) 0.91

Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS One (2013) 0.91

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget (2014) 0.91

Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf) (2015) 0.85

MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction. Patholog Res Int (2012) 0.84

Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. Am J Physiol Lung Cell Mol Physiol (2013) 0.83

Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene (2014) 0.83

Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features. Int J Clin Exp Pathol (2013) 0.83

Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways. Cancer Growth Metastasis (2015) 0.82

Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. Biomed Res Int (2014) 0.80

HGF-MET in cancer progression and biomarker discovery. Cancer Sci (2017) 0.80

Hepatocyte growth factor and basic fibroblast growth factor regulate atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease via the mitogen-activated protein kinase signaling pathway. Exp Ther Med (2013) 0.79

Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. Cancers (Basel) (2014) 0.79

miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression. Int J Mol Med (2016) 0.79

Artificial human Met agonists based on macrocycle scaffolds. Nat Commun (2015) 0.79

Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Biosci Rep (2015) 0.79

Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J Transl Med (2014) 0.78

Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res (2015) 0.77

Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma. Cancer Sci (2016) 0.77

Effects of hepatocyte growth factor on MMP-2 expression in scleral fibroblasts from a guinea pig myopia model. Int J Ophthalmol (2014) 0.77

Semi-synthesis of a HGF/SF kringle one (K1) domain scaffold generates a potent in vivo MET receptor agonist. Chem Sci (2015) 0.77

Differential Roles of Carboxylated and Uncarboxylated Osteocalcin in Prostate Cancer Growth. J Cancer (2016) 0.76

Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. PLoS One (2016) 0.76

Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma. Oncotarget (2016) 0.76

Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2016) 0.75

Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair. Expert Opin Ther Targets (2016) 0.75

The effects of serum from prostate cancer patients with elevated body mass index on prostate cancer cells in vitro. Lipid Insights (2015) 0.75

Stromal Androgen Receptor in Prostate Cancer Development and Progression. Cancers (Basel) (2017) 0.75

Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther (2015) 0.75

Identifying ultrasensitive HGF dose-response functions in a 3D mammalian system for synthetic morphogenesis. Sci Rep (2016) 0.75

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer (2016) 0.75

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res (2016) 0.75

(89)Zr-DFO-AMG102 Immuno-PET to Determine Local HGF Protein Levels in Tumors for Enhanced Patient Selection. J Nucl Med (2017) 0.75

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS. Cell Chem Biol (2017) 0.75

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. Cancers (Basel) (2017) 0.75

Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncol Lett (2017) 0.75

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94

Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (1987) 6.26

Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res (2007) 5.63

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23

Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int (2006) 4.87

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39

Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol (1993) 3.32

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J (1991) 3.20

Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12

Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01

c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81

Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell (2004) 2.61

The "Gab" in signal transduction. Trends Cell Biol (2003) 2.52

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39

A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther (2010) 2.18

A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol (2011) 2.11

HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem (2003) 2.08

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08

Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB. Cell (2007) 2.02

Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res (1994) 1.99

The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell (2004) 1.93

Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol (2011) 1.87

Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res (2006) 1.79

How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol (2003) 1.77

A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc Natl Acad Sci U S A (1992) 1.70

Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int (2001) 1.69

From Tpr-Met to Met, tumorigenesis and tubes. Oncogene (2007) 1.69

Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J (1992) 1.68

The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat Struct Biol (2003) 1.68

Structure of the semaphorin-3A receptor binding module. Neuron (2003) 1.63

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res (2006) 1.54

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem (2009) 1.47

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem (2011) 1.45

Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene (2007) 1.42

Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (2003) 1.42

Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem (2007) 1.34

Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis (2009) 1.26

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol (2011) 1.23

Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol (1994) 1.22

Scatter factors and invasive growth. Semin Cancer Biol (2001) 1.21

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res (2010) 1.20

Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem (1992) 1.17

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol (2009) 1.14

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene (1999) 1.14

Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res (2002) 1.14

MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res (2010) 1.13

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther (2010) 1.08

Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther (2004) 1.07

TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther (2010) 1.07

Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci U S A (1998) 1.07

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther (2011) 1.06

MET pathway as a therapeutic target. J Thorac Oncol (2009) 1.06

A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem (2008) 1.06

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res (2010) 1.06

Tyrosine kinase mutations in human cancer. Curr Mol Med (2007) 1.05

A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc Natl Acad Sci U S A (1997) 1.04

Hereditary papillary renal carcinoma type I. Curr Mol Med (2004) 1.03

E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci (2009) 1.02

Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos (2010) 1.01

Different point mutations in the met oncogene elicit distinct biological properties. FASEB J (2000) 1.01

Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett (1992) 1.00

Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ (1998) 0.98

Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J (1997) 0.96

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer (2009) 0.96

Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. FEBS Lett (2001) 0.96

Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. Biochem J (1998) 0.94

Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer (2010) 0.93

Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci (2009) 0.93

A mouse model of activating Met mutations. Cell Cycle (2005) 0.91

Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J Med Chem (2009) 0.89

Insights into function of PSI domains from structure of the Met receptor PSI domain. Biochem Biophys Res Commun (2004) 0.86

Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest (2008) 0.85

Expression of beta-catenin in renal cell carcinoma. Chin Med J (Engl) (2001) 0.84

Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat Res (2004) 0.82

In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor. J Med Chem (2010) 0.80

Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice. World J Gastroenterol (2005) 0.80

Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61

Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20

Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82

Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65

Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. Eur Urol (2008) 1.48

Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets (2008) 1.32

Cancer: Out of air is not out of action. Nature (2003) 1.30

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One (2013) 1.28

The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A (2006) 1.27

c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res (2006) 1.22

Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs (2006) 1.11

Hereditary papillary renal carcinoma type I. Curr Mol Med (2004) 1.03

Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res (2007) 1.01

Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther (2009) 0.96

Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. Mol Cancer Ther (2004) 0.95

VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol (2008) 0.95

Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell (2012) 0.95

Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res (2009) 0.89

Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med (2012) 0.89

Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J Med Chem (2009) 0.89

Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One (2012) 0.86

Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease. Cell Cycle (2006) 0.86

Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. Bioorg Med Chem Lett (2011) 0.83

Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells. J Cell Biochem (2010) 0.83

Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem (2014) 0.80

Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. Oncogene (2002) 0.80

Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. J Med Chem (2005) 0.79

Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides. Biopolymers (2011) 0.79

Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. J Nat Prod (2012) 0.79

Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis. Org Biomol Chem (2006) 0.79

Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist. J Med Chem (2008) 0.79

Direct application of keratinocyte growth factor, basic fibroblast growth factor and transforming growth factor-alpha during healing of tympanic membrane perforation in glucocorticoid-treated rats. Acta Otolaryngol (2002) 0.78

0.2 T magnetic field inhibits angiogenesis in chick embryo chorioallantoic membrane. Bioelectromagnetics (2004) 0.78

Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide. Mol Imaging (2015) 0.76

Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic. Bioorg Med Chem Lett (2005) 0.76

Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids. J Med Chem (2009) 0.76

A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation. Am J Physiol Lung Cell Mol Physiol (2010) 0.75

Novel antagonists of heparin binding growth factors. Oncotarget (2012) 0.75

Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function. Clin Cancer Res (2007) 0.75